Price
Target price
€53.76
€53.76
-4.210%
-2.36
-4.210%
€58.12
17:10 / Tradegate
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Halozyme Therapeutics Inc. Stock
Heavy losses for Halozyme Therapeutics Inc. today as the stock fell by -€2.360 (-4.210%).
With 24 Buy predictions and not a single Sell prediction Halozyme Therapeutics Inc. is an absolute favorite of our community.
With a target price of 58 € there is a slightly positive potential of 7.89% for Halozyme Therapeutics Inc. compared to the current price of 53.76 €.
Our community identified positive and negative aspects for Halozyme Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Halozyme Therapeutics Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | -4.210% | 4.390% | 4.042% | 53.291% | 65.790% | 57.067% | 276.745% |
| Ironwood Pharmaceuticals | 1.510% | 6.316% | 3.061% | -51.030% | -60.392% | -60.392% | -54.185% |
| Arrowhead Pharmaceuticals Inc. | 3.930% | -1.604% | -9.199% | -28.986% | -33.576% | -66.102% | -29.548% |
| Novocure Ltd | -2.190% | 1.503% | -2.218% | -12.320% | 11.173% | -85.811% | -77.946% |
Comments
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $60.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat